Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a cord tissue injection ease severe knee arthritis?

NCT ID NCT05079035

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tested whether a single injection of TTAX03, made from human amniotic and umbilical cord tissue, can reduce pain and improve function in people with advanced knee osteoarthritis (grades 3-4). 90 adults received either TTAX03 or a saline placebo, and researchers measured how many felt significant improvement after 12 weeks. The goal is to see if this biologic injection offers a new way to manage severe knee arthritis without surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TTAX03 (lyophilized and micronized human amniotic and umbilical cord tissue)
What this could lead to
If it works, this could provide a new, single-injection option to ease pain and improve knee function for people with advanced osteoarthritis.
What could go wrong
This is a small, early-phase trial (90 people) comparing the injection to saline, so results may not be conclusive or apply to everyone. There is also a risk of no significant benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

90 people

The number who actually took part.

Started

Dec 2021

Finished

Mar 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able and willing to provide written informed consent * ≥ 35 and ≤ 85 years of age (until a cap of 30 subjects \< 50 years of age is reached, at which point this will convert to ≥ 50 and ≤ 85 years of age) * Able to reliably complete the KOOS self-administered questionnaire * Clinical diagnosis of OA of the index knee, with pain onset more than one year prior to screening according to subject recall * KL grade 3 or 4 in the index knee * Pain score (KOOS) over the past week ≥ 70 in the index knee at Screening (the index knee will be the more painful knee by ≥ 20 in the case of bilateral disease) * A ≥ 3 months history of insufficient pain relief from IA hyaluronic acid or a ≥ 3 months history of insufficient pain relief from IA corticosteroids, unless they are medically contraindicated for the subject * A ≥ 3 months history of insufficient pain relief from other currently recommended treatments, including weight loss and physical therapy * Any two of the following: * Severe knee pain or stiffness that limits everyday activities, including walking, climbing stairs, and getting in and out of chairs. Finding it hard to walk more than a few blocks without significant pain and need to use a cane or walker * Moderate or severe knee pain while resting, either day or night * Chronic knee inflammation and swelling that does not improve with rest or medications * BMI ≤ 40 kg/m2 * Adequate bone marrow function (ANC \> 1000 × 109 /L, platelets ≥ 100,000 × 109 /L, Hgb ≥ 10 g/dL) * Adequate hepatic function (AST/ALT ≤ 1.5 × ULN, total bilirubin ≤ 1.2 × ULN) * Adequate renal function (creatinine ≤ 1.2 × ULN) * Negative urine test for opioids (including synthetic opioids) * If female and of child-bearing potential, willingness to use effective birth control during the study. Exclusion Criteria: * Cognitive impairment, mental illness, neuroses or untreated depression that would preclude understanding or reliably completing the patient reported outcome measures * Non-ambulatory, bedridden, or with active fibromyalgia, radiculopathy, painful peripheral neuropathy, vascular insufficiency, hip OA or other joint disease severe enough to prevent assessment of knee pain or causing functional impairment * Current use of opioid analgesics, or positive urine laboratory test for opiates during the screening period * Hyaluronic acid, corticosteroid, platelet rich plasma or stem cells IA knee injections within the prior 3 months, oral or intramuscular corticosteroids within the prior 2 months * Scheduled knee arthroscopy or knee surgery in either knee within 12 weeks from enrollment * Known or suspected joint infection of either knee * History of knee ligament surgery in the past 12 months * Acute injury to the knee in the past 3 months resulting in difficulty walking for more than 24 hours * History of inflammatory joint diseases, crystalline diseases such as gout or pseudogout, systemic lupus, rheumatoid arthritis, autoimmune disease or Crohn's disease * Previous repair of a cruciate ligament, osteochondral autograft transfer, mosaicplasty, subchondral surgery (subchondroplasty) or previously diagnosed subchondral insufficiency fracture * Comorbid conditions that include the following: known other causes of arthritis (infectious arthritis, or psoriatic arthritis), osteomyelitis, cardiopulmonary disease that limits walking more than knee pain, bone metastases or Paget's disease involving the lower extremities. * Psoriasis or other acute or chronic inflammatory conditions or infection affecting the skin over the index knee * Symptoms of locking, intermittent block to range of motion or loose body sensation which could indicate meniscal displacement or an intraarticular loose body in the index knee * Use of anticoagulants (except for ≤ 81 mg of aspirin per day) or a history of any coagulopathy or bleeding disorder, sickle cell disease * History of substance abuse in the past 2 years * Prior or current use of systemic immunosuppressive medications (other than corticosteroids for arthritis), chemotherapy, or history of organ transplant (kidney, heart, lung) * Prior radiation therapy to the index knee * Prior treatment with CLARIX FLO, NEOX FLO, or injectable birth tissue products for any indication * Concurrent treatment, or treatment in the past 90 days, with any investigational agent * Severe concurrent illness which, in the view of the investigator, would interfere with this 52 week study * Any condition which, in the opinion of the investigator, would make a patient a poor candidate for this study * Positive blood pregnancy test or known pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Knee arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Alabama Orthopaedic Center

    Birmingham, Alabama, 35243, United States

  • Gulfcoast Research Institute

    Sarasota, Florida, 34232, United States

  • Horizon Clinical Research

    La Mesa, California, 91942, United States

  • Manage Sites/The Ohio State University Wexner Medical Center, Sports Medicine The Ohio State University Wexner Medical Center, Sports Medicine

    Columbus, Ohio, 43201, United States

  • Ochsner Health Center

    Jefferson, Louisiana, 70121, United States

  • Paragon Sports Medicine

    Atlanta, Georgia, 30327, United States

  • Precision Clinical Research

    Sunrise, Florida, 33351, United States

  • Rothman Orthopaedic Institute

    Media, Pennsylvania, 19063, United States

  • Tuscon Orthopedic Institute

    Tucson, Arizona, 85712, United States

  • UAB Orthopaedic Surgery

    Birmingham, Alabama, 35205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.